CIK 0001595097 · Non-accelerated filer<br>Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464348039
- Phone
- 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +31,028 | $28.82 | $894K | 539,774 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +29,244 | $29.42 | $860K | 569,018 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +2,654 | $31.00 | $82K | 571,672 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +4,125 | $31.86 | $131K | 575,797 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +3,866 | $32.47 | $126K | 579,663 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +18,055 | $33.71 | $609K | 597,718 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +31,549 | $34.62 | $1.1M | 629,267 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +32,295 | $35.83 | $1.2M | 661,562 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +16,484 | $36.53 | $602K | 678,046 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +43,754 | $37.49 | $1.6M | 721,800 |
| 2024-01-26 | Cormorant Asset Management, LP 10% owner | Purchase | +3,200 | $38.49 | $123K | 725,000 |
| 2023-05-18 | Altmeyer Anne Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | Jenkins John Kenneth Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | Jacques Rachelle Suzanne Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | Salzmann Peter Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | HOLMER ALAN F Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | Ben Yong Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-05-18 | CATLIN AVERY W Director | Grant or award · Stock Option (right to buy) | +5,300 | 5,300 | ||
| 2023-03-06 | Ben Yong Director | Grant or award · Stock Option(right to buy) | +5,307 | 5,307 | ||
| 2023-02-13 | Brake Rachael Louise Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +1,400,000 | 1,400,000 |
Page 9 of 10 · 200 trades